Topical Corticosteroid (TCS) clinical trials

A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis

This study is looking into a new medicine called lebrikizumab for children and teenagers aged 6 months to 17 years who have moderate to severe eczema. We want to see how well it works, if it's safe, and how the body handles it.